Drug intelligence / Profile preview

doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid

Development stage: Preclinical
Lead developer: Shenyang Pharmaceutical University
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

Doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid (DOX@LR/oHA-APBA) is a pH-responsive, tumor-targeted nanohybrid formulation developed for the treatment of breast cancer. The formulation utilizes laponite RDS (LR) nanodisks as a drug carrier, where doxorubicin is loaded into the interlayer space via ion exchange. The nanodisks are then assembled with a targeted protection layer composed of oligomeric hyaluronic acid (oHA) conjugated to 3-aminophenylboronic acid (APBA). This system targets CD44 receptors overexpressed on cancer cells via the hyaluronic acid moiety, while the boronic acid groups can interact with sialic acid residues on tumor cell membranes. The nanohybrid exhibits acid-dependent, sustained release of doxorubicin in the acidic tumor microenvironment, enhancing cellular uptake and cytotoxicity against breast cancer cells.

Other names: DOX@LR/oHA-APBAdoxorubicin-loaded laponite/oligomeric hyaluronic acid-aminophenylboronic acid nanohybrids

Targets

TOP2A (DNA topoisomerase II)CD44 (CD44 antigen)DNA

Beyond the preview

Go deeper on doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + low molecular weight hyaluronic acid + aminophenylboronic acid.

Explore the full profile